Agilent Technologies (NYSE:A) updated its FY22 earnings guidance on Monday. The company provided earnings per share guidance of $4.76-4.86 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $4.78. The company issued revenue guidance of $6.65-6.73 billion, compared to the consensus revenue estimate of $6.75 billion.Agilent Technologies also updated its FY 2022 guidance to $4.760-$4.860 EPS.
Several brokerages have recently weighed in on A. Cowen increased their price objective on shares of Agilent Technologies from $180.00 to $187.00 and gave the company an outperform rating in a research report on Tuesday. KeyCorp upped their price target on shares of Agilent Technologies from $160.00 to $195.00 and gave the company an overweight rating in a research note on Wednesday, August 18th. Wells Fargo & Company upped their price target on shares of Agilent Technologies from $150.00 to $180.00 and gave the company an overweight rating in a research note on Wednesday, August 18th. Bank of America upped their price target on shares of Agilent Technologies from $177.00 to $179.00 and gave the company a buy rating in a research note on Tuesday. Finally, Citigroup upped their price target on shares of Agilent Technologies from $160.00 to $190.00 and gave the company a buy rating in a research note on Wednesday, August 18th. One analyst has rated the stock with a hold rating and eighteen have assigned a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of Buy and a consensus price target of $151.75.
Shares of A traded down $1.81 during mid-day trading on Thursday, reaching $152.97. The company had a trading volume of 2,291,394 shares, compared to its average volume of 1,621,541. The company’s 50 day simple moving average is $159.22 and its 200 day simple moving average is $154.31. Agilent Technologies has a 1-year low of $112.47 and a 1-year high of $179.57. The company has a debt-to-equity ratio of 0.55, a quick ratio of 1.63 and a current ratio of 2.11. The company has a market capitalization of $46.31 billion, a price-to-earnings ratio of 47.80, a P/E/G ratio of 2.67 and a beta of 0.98.
The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, January 26th. Investors of record on Tuesday, January 4th will be issued a $0.21 dividend. This represents a $0.84 dividend on an annualized basis and a yield of 0.55%. The ex-dividend date is Monday, January 3rd. This is a positive change from Agilent Technologies’s previous quarterly dividend of $0.19. Agilent Technologies’s dividend payout ratio (DPR) is 24.38%.
In other Agilent Technologies news, SVP Padraig Mcdonnell sold 1,500 shares of the firm’s stock in a transaction that occurred on Friday, November 19th. The shares were sold at an average price of $165.00, for a total transaction of $247,500.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.
A hedge fund recently raised its stake in Agilent Technologies stock. Morgan Stanley grew its position in shares of Agilent Technologies, Inc. (NYSE:A) by 2.9% in the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,154,775 shares of the medical research company’s stock after purchasing an additional 33,059 shares during the quarter. Morgan Stanley owned about 0.38% of Agilent Technologies worth $170,688,000 as of its most recent SEC filing.
About Agilent Technologies
Agilent Technologies, Inc engages in the provision of application focused solutions for life sciences, diagnostics, and applied chemical markets. It operates through the following segments: Life Sciences and Applied Markets; Diagnostics and Genomics; and Agilent CrossLab. The Life Sciences and Applied Markets segment offers application-focused solutions that include instruments and software that enable to identify, quantify, and analyze the physical and biological properties of substances and products, as well as the clinical and life sciences research areas to interrogate samples at the molecular and cellular level.
Featured Story: Quiet Period Expirations Explained
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.